# Elasmogen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/elasmogen

- Industry: Pharmaceuticals
- Headquarters: Aberdeen, UK
- Website: www.elasmogen.com
- Latest round: Seed (Mar 16, 2017)
- Investors on record: 2

## About

Elasmogen Ltd. is a biotechnology company focused on the discovery and development of innovative therapeutics using their proprietary biologics platform, soloMERs®, targeting diseases such as autoimmune disorders and various forms of cancer.Founded in 2016, Elasmogen Ltd. is headquartered in Aberdeen, UK. The company specializes in developing therapeutic solutions through its proprietary soloMER technology, which includes unique antibody-like proteins derived from shark immune systems. Caroline Barelle serves as both CEO and founder, with a history of involvement in biotechnology. Elasmogen has completed three deals, with the most recent funding round occurring on January 10, 2020, when it raised GBP 2 million from investor Deepbridge Capital. The total amount raised by the company is GBP 2 million.Elasmogen Ltd specializes in the discovery and development of therapeutics utilizing their proprietary biologics platform known as soloMERs®. These small, unique antibody-like proteins, derived from the immune systems of sharks, are designed to target a range of diseases, particularly autoimmune disorders and various forms of cancer. The soloMER technology enables the creation of multi-functional therapeutic products with differentiated binding interactions, thereby offering novel mechanisms of action. These therapeutics have potential applications in clinical settings, addressing unmet medical needs by improving patient outcomes and quality of life. Elasmogen serves a diverse clientele, including pharmaceutical companies and research institutions, across various geographical markets including North America, Europe, and Asia.Elasmogen generates revenue primarily through partnerships and licensing agreements for its patented soloMER technology and related products. The business structure is primarily B2B, where transactions typically involve collaborative agreements with pharmaceutical companies seeking to develop novel therapeutics leveraging Elasmogen's unique capabilities. Revenue streams may derive from upfront licensing fees, milestone payments, and royalties based on product sales. The company’s flagship products, particularly those developed for cancer treatment, are sold under licensing agreements, with a focus on creating tailored solutions that meet partner-specific requirements. These transactions reinforce Elasmogen's commitment to fostering innovative therapeutic solutions while enhancing its financial stability through strategic collaborations.Elasmogen plans to utilize the GBP 2 million raised in January 2020 to support the development of new products, including those targeting debilitating diseases in the oncology space. The company aims to expand into North America and Asia by 2025, capitalizing on its existing partnerships and exploring new opportunities to enhance its market presence. This strategic expansion will be complemented by ongoing research and development efforts to drive innovation in therapeutics.

## Funding rounds

- Seed, Mar 16, 2017 — Deepbridge Capital, Scottish Enterprise

## Investors

- Deepbridge Capital (https://capitalatlas.ai/funds/deepbridge-capital) — Seed
- Scottish Enterprise (https://capitalatlas.ai/funds/scottish-enterprise) — Seed